{"news_desk": "Business", "print_page": "3", "section_name": "Science", "subsection_name": null, "byline": {"contributor": "", "original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Spark Therapeutics announces success in late-stage test for medication used in treating inherited eye disease of retina that can cause blindness; is seeking to become first gene therapy to win approval from Food and Drug Administration. ", "type_of_material": "News", "word_count": "1035", "lead_paragraph": "Spark Therapeutics said the treatment had allowed people with certain so-called inherited retinal dystrophies to maneuver in dimmer light than they could before.", "pub_date": "2015-10-05T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Eye Treatment Closes In on Being First Gene Therapy Approved in U.S. ", "print_headline": "Eye Treatment Closes In on Being First Gene Therapy Approved in U.S. "}, "snippet": "Spark Therapeutics said the treatment had allowed people with certain so-called inherited retinal dystrophies to maneuver in dimmer light than they could before.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/10/05/science/eye-treatment-closes-in-on-being-first-gene-therapy-approved-in-us.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Spark Therapeutics Inc.", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Genetics and Heredity", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Eyes and Eyesight", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Genetic Engineering", "name": "subject"}], "blog": [], "_id": "5611f5c738f0d86550b9661c", "source": "The New York Times"}